SecBot SecBot
8-K ·Filed May 15, 2026

PULM

Pulmatrix, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001493152-26-023367
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will move on merger execution, not quarterly results. Monitor for regulatory and stockholder approvals for the Eos merger; failure to close would likely lead to cash depletion and delisting risk. The $1M preferred placement provides a short cash runway.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.25
T+0 close · May 15, 2026 · via day close
Latest settled
+28.00%
T+60 · $1.60
Vs SPY
+23.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $1.25entry
  2. T+1 · 6mo ago +0.80%α +0.86% · $1.26
  3. T+5 · 6mo ago +7.20%α +6.24% · $1.34
  4. T+20 · 5mo ago +12.80%α +10.68% · $1.41
  5. T+60 · 3mo ago +28.00%α +23.48% · $1.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood at $3.3M with a going-concern qualification. The company is pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, having raised $1M in a private placement. This is a minimal-event filing for a pre-revenue entity reliant on merger completion.

Key Financial Metrics

EPS
−$0.32
Revenue
$0.00

Key Facts

  • Net loss of $1.2M for Q1 2026 vs $1.8M in Q1 2025, improvement of 35%
  • Cash and equivalents of $3.3M as of March 31, 2026, down from $4.1M at year-end 2025
  • Financial statements prepared on a going-concern basis
  • All clinical development on hold while seeking to license or monetize assets
  • Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026
  • Raised $1M gross proceeds from private placement of Series B Convertible Preferred Stock

Financial Impact

Net loss improved to $1.2M from $1.8M; no revenue. Cash burn of ~$0.8M during the quarter.

cashnet loss

Risk Factors

  • Merger with Eos may not close, leaving the company without a viable path forward
  • Cash of $3.3M is insufficient for long-term operations without additional funding or deal completion
  • Ongoing going-concern qualification increases bankruptcy risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-023367
Document: form8-k.htm0001493152-26-023367
Document: 0001493152-26-023367-index-headers.html0001493152-26-023367
Document: 0001493152-26-023367-index.html0001493152-26-023367
Document: 0001493152-26-023367.txt0001493152-26-023367
8-K Data (Synthetic)0001493152-26-023367

Track record

21 reports on PULM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
  2. Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
  3. Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
  4. Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
  5. Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
  6. Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
  7. Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
  8. Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  9. Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  10. Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026